摘要
目的探讨N-乙酰半胱氨酸(NAC)治疗慢性阻塞性肺疾病(COPD)的临床疗效和作用机制。方法将78例COPD患者随机分为治疗组和对照组,观察其治疗前后对痰液炎症细胞计数及核因子-kB(NF-kB)、白细胞介素8(IL-8)、肿瘤坏死因子α(TNF-α)水平的影响,以及对临床症状、肺功能指标和血丙二醛(MDA)、全血超氧化物歧化酶(SOD)和血清血管紧张素Ⅰ转换酶(ACE)活性及血内皮素-1(ET-1)含量的变化情况,并与20名健康人作比较。结果78例COPD患者中脱落5例(治疗组3例,对照组2例)。NAC治疗COPD的总显效率为72.50%,总有效率为87.50%,与对照组比较有显著性差异(P<0.05)。与对照组比较,治疗组能明显改善肺功能指标(FEV1、FVC、mPAP)和血MDA、SOD、ACE活性及ET-1含量(P<0.05)。治疗后治疗组痰液中性粒细胞(PMN)、非中性粒细胞(mPMN);IL-8、TNF-α和NF-kB活性(A值)较治疗前显著降低(P<0.01),降低作用优于对照组(P<0.05),治疗期间未见明显毒副作用。结论NAC治疗COPD患者可改善其临床症状和肺功能,安全性良好,通过增强抗氧化能力和减轻COPD患者气道炎症反应而发挥其治疗作用。
AIM: To explore the clinical effect and mechanism of NAC on patients with chronic obstructive pulmonary disease ( COPD ). METHODS: 78 patients with COPD in stable phase were randomly divided into the treated group and the control group. Total and differential count of inflammatory cell in sputum, NF-kB, IL-8, TNF-α, and clinical symptom, FVC, FEV1, mPAP and the blood levels of malondialdchyde (MDA), superoxide dismutase (SOD), angiotensin-converting enzyme (ACE) and endothelins-1 (ET-1) were measured before and after treatment. RESULTS:5 cases of the 78 patients dropped out. The rate of total marked effect and total effect were 72.50%, and 87.50% respectively, in the treated group. All the indexes measured in patients before and after treatment were significantly different from those in healthy subjects ( P 〈 0.05). Differential count of polymorphonuclear neutrophil (PMN), the levels of IL-8 and TNF-α, the activity of NF-kB in sputum in the treated group decreased after treatment (P 〈 0.01), while the FEV1, FVC, mPAP, MDA, SOD, ACE, and ET-1 were ameliorated (P 〈 0.05), and all were better than those in the control group ( P 〈 0.05). No obvious adverse effects were found. CONCLUSION: NAC used for treating COPD is able to relive the clinical symptom and improve the lung function, with a fairly good safety, and can play a therapeutic role on patients with COPD by way of increasing anti-oxidative ability and reducing the airway inflammatory reaction.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2005年第12期1423-1426,共4页
Chinese Journal of Clinical Pharmacology and Therapeutics